Not Yet RecruitingPhase 3ACTRN12612000344897
Intravitreal Steroid for Anterior Ischemic Optic Nerve disease.
The effect of intravitreal triamcinolone on best corrected visual acuity (BCVA) and visual field in patients with non-arteritic anterior ischemic optic neuropathy.
Sponsor
Khon Kaen University
Enrollment
20 participants
Start Date
Apr 1, 2012
Study Type
Interventional
Conditions
Summary
The purpose of this study was to determine the effect of intravitreal triamcinolone acetonide (IVTA), compared to careful observation, in restoration of optic nerve functions.
Eligibility
Sex: Both males and femalesMin Age: 50 YearssMax Age: 75 Yearss
Inclusion Criteria5
- acute painless visual loss
- localized optic disc edema
- no associated symptoms (; i.e. headache/scalp tenderness/jaw claudication)
- unilateral involvement with the normal fellow eye
- no previous attack or treatment
Exclusion Criteria2
- ocular and/or orbital infection
- other ocular disease that might interfere with visual acuity and/ or the visual field
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
An intravitreal injection of 4 mg/0.1ml triamcinolone acetonide
An intravitreal injection of 4 mg/0.1ml triamcinolone acetonide
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000344897